Effect of Selective iNOS Inhibition During Human Endotoxemia
Primary Purpose
Endotoxemia
Status
Completed
Phase
Phase 1
Locations
Netherlands
Study Type
Interventional
Intervention
Aminoguanidine
endotoxin
Sponsored by
About this trial
This is an interventional prevention trial for Endotoxemia focused on measuring Endotoxemia, Aminoguanidine
Eligibility Criteria
Inclusion Criteria: Healthy volunteers Exclusion Criteria: tendency towards fainting alcohol abuse nicotine abuse drugs abuse
Sites / Locations
- Radboud University Nijmegen Medical Centre
Outcomes
Primary Outcome Measures
Hemodynamics
Markers of Inflammation
Cytokines
Markers of Renal Injury
Inducible NO synthase expression
NO-metabolites
Mediators of Vascular reactivity
Sensitivity to norepinephrine
Endothelial-dependent vasorelaxation
Secondary Outcome Measures
Full Information
NCT ID
NCT00184990
First Posted
September 12, 2005
Last Updated
April 14, 2008
Sponsor
Radboud University Medical Center
1. Study Identification
Unique Protocol Identification Number
NCT00184990
Brief Title
Effect of Selective iNOS Inhibition During Human Endotoxemia
Official Title
Effect of Selective iNOS Inhibition During Human Endotoxemia
Study Type
Interventional
2. Study Status
Record Verification Date
April 2008
Overall Recruitment Status
Completed
Study Start Date
January 2005 (undefined)
Primary Completion Date
September 2005 (Actual)
Study Completion Date
September 2005 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
Radboud University Medical Center
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Sepsis or endotoxemia is manifested by hypotension, resistance to vasopressors, myocardial depression,and altered organ blood flow distribution. The mechanisms underlying the cardiovascular dysfunction during sepsis are complex; however, they are partially mediated by an uncontrolled production of NO by inducible NO synthase (iNOS).Control subjects received 2 ng/kg E. coli endotoxin, whereas the active intervention group received endotoxin in the presence of selective iNOS-inhibitor aminoguanidine. Hemodynamics, vascular responses to norepinephrine, acetylcholine and sodium nitroprusside, as well as circulating cytokines and other mediators of inflammation were measured. We tested the hypothesis that inhibition of NO-synthesis prevented the LPS-mediated insensitivity to noradrenalin and endothelial-dependent vasorelaxation. Furthermore, we tested whether NO participates in occurrence of the endotoxin tolerance in humans by using the iNOS inhibitor aminoguanidine on healthy volunteers with endotoxemia. At 0; 2 and 4 hours after the LPS challenge whole blood was stimulated with five TLR agonists in vitro and pro- and anti-inflammatory cytokines were measured.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Endotoxemia
Keywords
Endotoxemia, Aminoguanidine
7. Study Design
Primary Purpose
Prevention
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
7 (Actual)
8. Arms, Groups, and Interventions
Intervention Type
Drug
Intervention Name(s)
Aminoguanidine
Intervention Type
Drug
Intervention Name(s)
endotoxin
Primary Outcome Measure Information:
Title
Hemodynamics
Time Frame
24 hrs after LPS administration
Title
Markers of Inflammation
Time Frame
24 hrs after LPS administration
Title
Cytokines
Time Frame
24 hrs after LPS administration
Title
Markers of Renal Injury
Time Frame
24 hrs after LPS administration
Title
Inducible NO synthase expression
Time Frame
24 hrs after LPS administration
Title
NO-metabolites
Time Frame
24 hrs after LPS administration
Title
Mediators of Vascular reactivity
Time Frame
24 hrs after LPS administration
Title
Sensitivity to norepinephrine
Time Frame
24 hrs after LPS administration
Title
Endothelial-dependent vasorelaxation
Time Frame
24 hrs after LPS administration
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
35 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Healthy volunteers
Exclusion Criteria:
tendency towards fainting
alcohol abuse
nicotine abuse
drugs abuse
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Peter Pickkers, PhD
Organizational Affiliation
Radboud University Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Radboud University Nijmegen Medical Centre
City
Nijmegen
State/Province
Gelderland
ZIP/Postal Code
6500HB
Country
Netherlands
12. IPD Sharing Statement
Learn more about this trial
Effect of Selective iNOS Inhibition During Human Endotoxemia
We'll reach out to this number within 24 hrs